Yariv Mazor, Ph.DExecutive Director and Head of Protein Engineering & Novel Modalities at AstraZenecaSpeaker
Profile
Dr. Yariv Mazor is Executive Director and Head of Protein Engineering & Novel Modalities at AstraZeneca’s Biologics Engineering division. Since joining AstraZeneca in 2009, Dr. Mazor has pioneered multiple antibody platform technologies, including the DuetMab bispecific, TriMab trispecific, TEDx immune engager, and guided-pMHC staging (GPS) platforms. Under his leadership, five DuetMab programs have advanced into clinical development, including Volrustomig, Rilvegostomig, Sabestomig, Tilatamig Samrotecan, and AZD2068 (cMET/EGFR RC). Dr. Mazor earned his Ph.D. in Biotechnology from Tel Aviv University and completed postdoctoral training in Chemical Engineering at the University of Texas at Austin. He is a co-inventor on more than 30 patents and patent applications and has authored over 30 peer-reviewed publications in the field of biologics engineering.
Agenda Sessions
Conditional by Design – Engineering Synapse-Gated, Dual-targeting Trispecific T-Cell Engagers for an Improved Therapeutic Index
, 16:15View Session